Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.64 |
| ▸ | FNTA | P49354 | 12/20 | 0.61 |
| ▸ | FNTB | P49356 | 12/20 | 0.61 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6163431 | 0.90 | FNTA (0.75) | CYP3A4FNTAFNTB | |
| Tipifarnib SCHEMBL29352433 | 0.86 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL21544535 | 0.86 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| (S)-Tipifarnib SCHEMBL30436988 | 0.86 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL8097 | 0.86 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL23633189 | 0.86 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| (S)-Tipifarnib SCHEMBL4429738 | 0.86 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL22772860 | 0.86 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL29371885 | 0.86 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL94807 | 0.86 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557847-B2 | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-8557847-B2 | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20120196766-A1 | Therapeutic Use of Farnesyltransferase Inhibitors and Methods of Monitoring the Efficacy Thereof | FOURIE ANNE MADELEINE (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196766-A1 | Therapeutic Use of Farnesyltransferase Inhibitors and Methods of Monitoring the Efficacy Thereof | FOURIE ANNE MADELEINE (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2362218-A2 | Methods of monitoring the efficacy of farnesyltransferase inhibitors | Janssen Pharmaceutica N.V. (BE) | 2011-08-31 | — | — | EP | disclosed |
| US-20110195419-A1 | THERAPEUTIC USE OF FARNESYLTRANSFERASE INHIBITORS AND METHODS OF MONITORING THE EFFICACY THEREOF | FOURIE ANNE MADELEINE | 2011-08-11 | — | — | US | disclosed |
| US-20110195419-A1 | THERAPEUTIC USE OF FARNESYLTRANSFERASE INHIBITORS AND METHODS OF MONITORING THE EFFICACY THEREOF | FOURIE ANNE MADELEINE | 2011-08-11 | — | — | US | disclosed |
| US-20110098318-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING BREAST CANCER | PALMER PETER ALBERT | 2011-04-28 | — | — | US | disclosed |
| US-20110098318-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING BREAST CANCER | PALMER PETER ALBERT | 2011-04-28 | — | — | US | disclosed |
| US-20090197913-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | BAUMANN CHRISTIAN ANDREW | 2009-08-06 | — | — | US | disclosed |
| US-20090197913-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | BAUMANN CHRISTIAN ANDREW | 2009-08-06 | — | — | US | disclosed |
| US-20090018164-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING BREAST CANCER | PALMER PETER ALBERT | 2009-01-15 | — | — | US | disclosed |
| US-20090018164-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING BREAST CANCER | PALMER PETER ALBERT | 2009-01-15 | — | — | US | disclosed |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098318-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING BREAST CANCER | FNTA, FNTB, LCAT | CYP3A4 1349/4885FNTA 1/4885FNTB 2/4885 |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | FLT3, MCL1, CDC42BPG | CYP3A4 1975/4885FNTA 755/4885FNTB 193/4885 |
| US-20090018164-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING BREAST CANCER | FNTA, FNTB, LCAT | CYP3A4 1349/4885FNTA 1/4885FNTB 2/4885 |
| US-20090197913-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | FLT3, MCL1, CSF1R | CYP3A4 2047/4885FNTA 74/4885FNTB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.